Ester Aparicio Prats
Tècnic/a superior de laboratori
Grup de recerca
Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic.
Impact of Dolutegravir plus Lamivudine as First-Line Antiretroviral Treatment on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood.
Genetic and catalytic efficiency structure of an HCV protease quasispecies.
IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.